Drug class
Cytochrome P450 17A1 Inhibitor
Mechanism of action
Abiraterone acetate is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17).
General use cases
- Prostatic Neoplasms, Castration-Resistant
- patients with metastatic castration-resistant prostate cancer
- patients with metastatic castration-resistant prostate cancer (CRPC)
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
